Cardiometabolic Health Congress (CMHC)
Avatar

47 y/o Male Referred for Evaluation of Obesity, Type 2 Diabetes & Dyspnea on Exertion: Incorporating SGLT-2 Inhibitors in T2DM for Cardiorenal Protection

By Cardiometabolic Health Congress (CMHC) FEATURING George Bakris, Stephen D. Wiviott, Robert Eckel
By Cardiometabolic Health Congress (CMHC) FEATURING George Bakris, Stephen D. Wiviott, Robert Eckel
575 views
September 22, 2020
1 Comment
Login to view comments. Click here to Login

Featured Video

18:06
Lilly Obesity

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Featured Video

18:06
Lilly Obesity

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Related Content

AUTOPLAY
47:11
Houston Methodist Hospital

The Protein Myth: Our Obsession With Protein and How It Is Killing US

Feat. G. Davis
64:45
Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

Primer on Diabetes Management

Feat. S. Inzucchi
49:21
Physicians Committee for Responsible Medicine

Health of Vegetarians and Vegans: Findings From EPIC-Oxford and Othe…

Feat. T. J. Key
11:37
ACC 2022 Conference Coverage

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

Feat. P. Heidenreich
11:25
ACC 2023 Conference Coverage

ACC 2023: SGLT2i Use - Dos and Don'ts

Feat. A. Armbruster
23:35
Practical Ways to Achieve Targets in Diabetes Care

Is There a Future for HbA1c? (Moving Towards CGM: GMI and TIR)

Feat. I. Hirsch
18:43
ASPC 2019 Congress on CVD Prevention

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

Feat. R. DeFronzo
15:06
Robert Busch

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

26:01
Cardiology Fiesta 2017

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Feat. R. DeFronzo
37:21
University of Colorado Department of Medicine

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

Feat. R. Johnson
12:26
Juan Frias

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

15:33
Ken Fujioka

Could GLP-1's be a 'Game Changer' For Weight Loss? Ca…

17:44
Rita Jermyn

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

27:24
Cardiometabolic Health Congress (CMHC)

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Feat. L. Sloan
26:32
Practical Ways to Achieve Targets in Diabetes Care

Metabolic Surgery vs. Pharmacotherapy for Treatment of Obesity

Feat. S. Nissen
26:49
Diana Isaacs

Tirzepatide Updates

44:43
Jason Fung

Type 2 Diabetes Aetiology and Reversibility

14:19
UChicago Medicine

S-QUAD Therapy and Beyond: HFpEF in 2024

Feat. M. Belkin
23:21
Practical Ways to Achieve Targets in Diabetes Care

TIR vs. A1c: Q&A/ Panel Discussion

Feat. J. Skyler, G. Aleppo, T. Danne, L. Barbour
19:30
ACC 2022 Conference Coverage

Hot Topics in Heart Failure ACC.22

Feat. N. Ibrahim